[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schwannoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schwannoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,72,97,123,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100483520","longitudinal-prospective-study-of-neurocognition--neuroimaging-in-primary-bt-patients-100483520",false,"NCT05576103","Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients","Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging Outcomes in Primary Brain Tumor Patients Receiving Brain Radiotherapy","Inclusion Criteria:\n\n1. Patients 18 years or older\n2. Karnofsky performance status (KPS) ≥70\n3. Life expectancy of ≥1 year\n4. Primary brain tumor patients who will receive fractionated partial brain RT\n5. Able to complete neurocognitive assessments\n\nExclusion Criteria:\n\n1. Inability to undergo MRI with contrast\n2. Prior brain RT","ALL","18 Years","99 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.",[25,26,27,28],"Primary Brain Tumor","Glioma","Meningioma","Schwannoma","RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-10","ACTUAL",{"date":35,"type":33},"2015-01",{"date":37,"type":21},"2030-12",{"name":39,"class":40},"Jona Hattangadi-Gluth","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100383857","hypofractionated-proton-therapy-for-benign-intracranial-brain-tumors-the-hippi-study-100383857","NCT04278118","Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study","HiPPI: A Phase 2 Trial of Hypofractionated Pencil Beam Scanning Proton Therapy for Benign Intracranial Tumors","HiPPI","Inclusion Criteria:\n\n* Pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. World Health Organization (WHO) grade 2-3 meningiomas are also allowed\n* Recommended to receive proton or photon fractionated radiation therapy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnant females are excluded. Female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. FCBP must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n\n  * A female of childbearing potential (FCBP) is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (if age \\>= 55 years); if the female subject is \\\u003C 55 years and she has been naturally postmenopausal for \\>= 1 year her reproductive status has to be verified by additional laboratory (lab) tests (\\\u003C 20 estradiol OR estradiol \\\u003C 40 with follicle stimulating hormone \\[FSH\\] \\> 40 in women not on estrogen replacement therapy)\n* Prior radiation therapy that would overlap with current target volume\n* Inability to undergo magnetic resonance imaging (MRI)",{"count":51,"type":21},70,"INTERVENTIONAL",[54],"NA","This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.",[57,58,59,60,61,62,28],"Grade I Meningioma","Grade II Meningioma","Grade III Meningioma","Intracranial Neoplasm","Nerve Sheath Neoplasm","Pituitary Gland Adenoma","2026-02-12",{"date":65,"type":33},"2026-02-17",{"date":67,"type":33},"2020-02-18",{"date":69,"type":21},"2031-12-01",{"name":71,"class":40},"Emory University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":52,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100449960","evaluation-of-the-convivo-system-100449960","NCT05139277","Evaluation of the CONVIVO System","Clinical Investigation to Evaluate the CONVIVO System for Discrimination of Normal From Abnormal Tissue During Brain Tumor Resection","Inclusion Criteria:\n\n* Adult patients (age\\>18)\n* Adults presenting with suspected intracranial gliomas (including glioblastoma), cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who are surgical candidates\n* Adults able to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Children (age \\\u003C18 years)\n* Fluorescein sodium (FNa) allergy",{"count":80,"type":21},30,[54],"The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and conventional histologic interpretation.",[84,85,86,27,28,87],"Glioblastoma","Glial Tumor","Brain Metastases","Pituitary Tumor","2026-02-04",{"date":90,"type":33},"2026-02-06",{"date":92,"type":33},"2022-06-28",{"date":94,"type":21},"2026-10",{"name":96,"class":40},"Dartmouth-Hitchcock Medical Center",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":121,"locationsCount":41},"100598949","multicenter-observational-study-of-multimodal-ai-for-upper-gi-mesenchymal-tumor-diagnosis-100598949","NCT07078136","Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis","Multicenter Observational Study of a Multimodal AI Model Using EUS, White-Light Endoscopy, and Clinical Data for Diagnosis of Upper GI Mesenchymal Tumors and Risk Stratification of Gastric GISTs","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients with an upper gastrointestinal subepithelial lesion (SEL) identified by white-light endoscopy and who have completed an endoscopic ultrasound (EUS) examination\n* Patients with a histopathological diagnosis of GIST confirmed by surgical or endoscopic resection, or other SELs confirmed by surgical resection, EUS-guided sampling, or other biopsy techniques\n* EUS image quality meets the following quality control standards\n\n  1. Equipment requirements: Olympus EU-ME2\u002FME1 processor (Olympus Medical Systems Corp., Tokyo, Japan); radial EUS scope (GF-UE260\u002FGF-UE240; Olympus, Tokyo, Japan) or linear EUS scope (GF-UCT260\u002FGF-UCT240; Olympus, Tokyo, Japan); miniature probe (UM2R\u002F3R; Olympus, Tokyo, Japan); Pentax ARIETTA 850 processor (Pentax, Tokyo, Japan); radial EUS scope (EG-3670URK, Pentax, Tokyo, Japan); linear EUS scope (EG-3870UT, Pentax, Tokyo, Japan); Fujifilm SU-8000 or SU-9000 processor; linear EUS scope (EG-580UT, Fujifilm, Tokyo, Japan); radial EUS scope (EG-580UR, Fujifilm, Tokyo, Japan)\n  2. EUS images clearly showing the lesion and surrounding tissue characteristics (at least 5 images or video); must include at least one image of the maximum lesion diameter, one image showing the layer of origin, and one image demonstrating the growth pattern (intraluminal\u002Fextraluminal)\n  3. EUS images must not contain artificial annotations, such as measurement scales, biopsy needles, Doppler signals, or elastography overlays\n  4. Image resolution must be at least 448 × 448 pixels\n* WLE (white-light endoscopy) image quality meets the following standards: images must clearly show the lesion location, mucosal features, and margins; at least one close-up and one distant view\n* Complete clinical data and histopathological reports must be available\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Absolute contraindications for EUS examination, history of gastric surgery, pregnancy, severe comorbidities, or known allergy to anesthetic agents\n* EUS examination terminated prematurely due to esophageal stricture, obstruction, large space-occupying lesions, rapid changes in heart rate or respiratory rate, patient intolerance, or excessive residual food\n* EUS image quality does not meet the required quality control standards\n* Pathological specimens do not meet diagnostic requirements: insufficient biopsy tissue (only R0 resection specimens are accepted for the GIST group), or incomplete immunohistochemical staining (missing CD117\u002FCD34\u002FDOG-1 expression report for the GIST group)\n* Pathological results indicate that the lesion is a metastatic tumor originating from another site",{"count":105,"type":21},130,"This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.",[108,109,110,28],"Submucosal Tumor","Gastrointestinal Stromal Tumor (GIST)","Leiomyoma",[112,113,114],"Artificial Intelligence","Endoscopic ultrasound","white-light endoscopy","2025-07-28",{"date":117,"type":33},"2025-07-31",{"date":115,"type":33},{"date":120,"type":21},"2026-06",{"name":122,"class":40},"Huazhong University of Science and Technology",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":22,"phases":4,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100458790","seoul-cohort-of-brain-tumor-monitoring-study-solomon-100458790","NCT05254197","SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)","The Risk of Growth in Patients With Non-malignant Brain Tumor: SeOuL cOhort of Brain Tumor MONitoring (SOLOMON) Study","SOLOMON","Inclusion Criteria for retrospective cohort\n\n* Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998\n* Asymptomatic at first visit to the hospital\n* Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit\n* Patients who have had two or more MRs at least 3 months apart\n* No previous radiotherapy or radiosurgery for the brain lesion\n* 18 years old or more\n\nInclusion Criteria for prospective cohort\n\n* Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less\n* Asymptomatic at first visit to the hospital\n* Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams\n* No previous radiotherapy or radiosurgery for the brain lesion\n* 18 years old or more\n* Patients who agree to participate by written consent\n\nExclusion Criteria\n\n* Patients who lost follow-up before the second MR exam\n* Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam\n* Patients suspected to have other than a neoplasm at follow-up MR exams",{"count":132,"type":21},3000,"15 Years","The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.",[136,27,28,137,138],"Brain Tumor, Primary","Pituitary Adenoma","Gliomas Benign",[140,141,27,28,142,143],"Non-malignant brain tumor","Benign brain tumor","Pituitary adenoma","Benign glioma","2024-11-30",{"date":146,"type":33},"2024-12-03",{"date":148,"type":33},"2001-01-01",{"date":150,"type":21},"2035-12-31",{"name":152,"class":40},"Seoul National University Hospital",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":22,"phases":4,"briefSummary":164,"conditions":165,"keywords":172,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":41},"100548500","establishing-prospective-mediastinal-tumor-database-of-pumch-100548500","NCT06421805","Establishing Prospective Mediastinal Tumor Database of PUMCH","A Single-center, Prospective, and Observational Study on Population Characteristics, Pathological Features, and Prognostic Factors of Patients With Mediastinal Tumor: Establishing Mediastinal Tumor Database of PUMCH.","MTDPUMCH","Inclusion Criteria:\n\n1. Clinical or pathological diagnosis of mediastinal tumors;\n2. Written consent is able to obtained.\n\nExclusion Criteria:\n\n1\\. Incomplete clinicopathological information.",{"count":162,"type":21},2000,"20 Years","This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors. Clinical information will be structured and processed, and it is recommended to establish a mediastinal tumors database at Peking Union Medical College Hospital. The goal is to provide support for the quality of diagnosis and treatment, clinical protocols, and medical decision-making related to mediastinal tumors.",[166,167,168,169,170,171,28],"Thymic Epithelial Tumor","Teratoma","Thymic Cyst","Retrosternal Goitre","Germ Cell Tumor","Lymphoma",[173,174,175],"mediastinal tumors","database","thymic epithelial tumor","2024-05-14",{"date":178,"type":33},"2024-05-20",{"date":180,"type":33},"2012-01-01",{"date":182,"type":21},"2045-12-30",{"name":184,"class":40},"Peking Union Medical College Hospital"]